Potential role of genetic polymorphisms in neoadjuvant chemotherapy response in breast cancer

被引：1
作者：
Bouhniz, Om Elez [1 ,2 ]
Kenani, Abderraouf [1 ]
机构：
[1] Univ Monastir, Fac Med Monastir, Res Lab Environm Inflammat Signaling & Pathol LR18, Monastir, Tunisia
[2] Univ Monastir, Fac Med Monastir, Res Lab Environm Inflammat Signaling & Pathol LR18, Monastir 5019, Tunisia
来源：
JOURNAL OF CHEMOTHERAPY | 2025年 / 37卷 / 02期
关键词：
Genetic polymorphisms; genes; neoadjuvant chemotherapy; breast cancer; therapy resistance; personalized medicine; PATHOLOGICAL RESPONSE; DRUG-RESISTANCE; ANTICANCER DRUG; IN-VITRO; P53; ASSOCIATION; EXPRESSION; CYTOCHROME-P450; THERAPY; ALLELE;
D O I：
10.1080/1120009X.2024.2330241
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Chemoresistance leads to treatment failure, which can arise through different mechanisms including patients' characteristics. Searching for genetic profiles as a predictor for drug response and toxicity has been extensively studied in pharmacogenomics, thus contributing to personalized medicine and providing alternative treatments. Numerous studies have demonstrated significant evidence of association between genetic polymorphisms and response to neoadjuvant chemotherapy (NAC) in breast cancer. In this review, we explored the potential impact of genetic polymorphisms in NAC primary resistance through selecting a specific clinical profile. The genetic variability within pharmacokinetics, pharmacodynamics, DNA synthesis and repair, and oncogenic signaling pathways genes could be predictive or prognostic markers for NAC resistance. The clinical implication of these results can help provide individualized treatment plans in the early stages of breast cancer treatment. Further studies are needed to determine the genetic hosts of primary chemoresistance mechanisms in order to further emphasize the implementation of genotypic approaches in personalized medicine.
引用
收藏
页码：97 / 111
页数：15
相关论文
共 84 条
[21]   Genetic Influences in Breast Cancer Drug Resistance [J].
Daniyal, Adhitiya ;
Santoso, Ivana ;
Gunawan, Nadira Hasna Putri ;
Barliana, Melisa Intan ;
Abdulah, Rizky .
BREAST CANCER-TARGETS AND THERAPY, 2021, 13 :59-85
[22]   RETRACTED: Drug-metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort (Retracted Article. See vol 24, pg 3315, 2006) [J].
DeMichele, A ;
Aplenc, R ;
Botbyl, J ;
Colligan, T ;
Wray, L ;
Klein-Cabral, M ;
Foulkes, A ;
Gimotty, P ;
Glick, J ;
Weber, B ;
Stadtmauer, E ;
Rebbeck, TR .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (24) :5552-5559
[23]   One-Carbon Metabolism in Health and Disease [J].
Ducker, Gregory S. ;
Rabinowitz, Joshua D. .
CELL METABOLISM, 2017, 25 (01) :27-42
[24]   The association between the T309G polymorphism of the MDM2 gene and sensitivity to anticancer drug is dependent on the p53 mutational status in cellular models [J].
Faur, N. ;
Araud, L. ;
Laroche-Clary, A. ;
Kanno, J. ;
Toutain, J. ;
Yamori, T. ;
Robert, J. ;
Le Morvan, V. .
BRITISH JOURNAL OF CANCER, 2009, 101 (02) :350-356
[25]   Evaluation of miRNA-196a2 and apoptosis-related target genes: ANX41, DFFA and PDCD4 expression in gastrointestinal cancer patients: A pilot study [J].
Fawzy, Manal S. ;
Toraih, Eman A. ;
Ibrahiem, Afaf ;
Abdeldayem, Hala ;
Mohamed, Amany O. ;
Abdel-Daim, Mohamed M. .
PLOS ONE, 2017, 12 (11)
[26]   A Single-Nucleotide Polymorphism in the MDR1 Gene as a Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer [J].
George, Joseph ;
Dharanipragada, Kadambari ;
Krishnamachari, Srinivasan ;
Chandrasekaran, Adithan ;
Sam, Soya Sisy ;
Sunder, Elangovan .
CLINICAL BREAST CANCER, 2009, 9 (03) :161-165
[27]   Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer - The potential and the questions [J].
Goble, S ;
Bear, HD .
SURGICAL CLINICS OF NORTH AMERICA, 2003, 83 (04) :943-+
[28]   CHARACTERIZATION OF HUMAN CYTOCHROME-P450 ENZYMES [J].
GUENGERICH, FP .
FASEB JOURNAL, 1992, 6 (02) :745-748
[29]   Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (Review) [J].
Hafsi, Sameh ;
Pezzino, Franca Maria ;
Candido, Saverio ;
Ligresti, Giovanni ;
Spandidos, Demetrios A. ;
Soua, Zohra ;
McCubrey, James A. ;
Travali, Salvatore ;
Libra, Massimo .
INTERNATIONAL JOURNAL OF ONCOLOGY, 2012, 40 (03) :639-644
[30]   ERα determines the chemo-resistant function of mutant p53 involving the switch between lincRNA-p21 and DDB2 expressions [J].
He, Yu-Hao ;
Yeh, Ming-Hsin ;
Chen, Hsiao-Fan ;
Wang, Tsu-Shing ;
Wong, Ruey-Hong ;
Wei, Ya-Ling ;
Huynh, Thanh Kieu ;
Hu, Dai-Wei ;
Cheng, Fang-Ju ;
Chen, Jhen-Yu ;
Hu, Shu-Wei ;
Huang, Chia-Chen ;
Chen, Yeh ;
Yu, Jiaxin ;
Cheng, Wei-Chung ;
Shen, Pei-Chun ;
Liu, Liang-Chih ;
Huang, Chih-Hao ;
Chang, Ya-Jen ;
Huang, Wei-Chien .
MOLECULAR THERAPY-NUCLEIC ACIDS, 2021, 25 :536-553
123456789